This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Educational Activity

Cost-Effectiveness Measures, Methods, and Policy Implications From the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for Schizophrenia

Robert A. Rosenheck, MD, and Chair, Jeffrey A. Lieberman, MD

Published: February 15, 2007

This CME activity is expired. For more CME activities, visit
Find more articles on this and other psychiatry and CNS topics:
The Journal of Clinical Psychiatry
The Primary Care Companion for CNS Disorders

Article Abstract

Salesof atypical antipsychotics have expanded rapidly as their use for treatment ofschizophrenia and other illnesses has increased. The CATIE trial was designedto evaluate the cost-effectiveness of these medications. Cost-effectivenessanal’ ‹ysis in CATIE examined the benefits and costs of treatments and attemptedto determine whether one treatment would result in better outcomes and lowercosts than another one. While the data from CATIE on cost-effectiveness havenot been analyzed yet, it is still possible to consider the potential implicationsof the analysis, including how the roles of researchers and stakeholders shouldbe considered in deciding optimal clinical practices and public policies.

See the entire activity.

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 68

Quick Links: